Mezzion Pharmaceuticals has announced the completion of an institutional financing round to support continued execution of the FUEL-2 trial, its global Phase III study evaluating udenafil (Jurvigo) in adolescents and young adults with Fontan circulation — a structural cardiac condition for which no therapy is currently approved specifically for this patient population.
The FUEL-2 trial (Fontan Udenafil Exercise Longitudinal Assessment Trial - 2) is a Phase III, confirmatory study being conducted across leading pediatric congenital heart centers internationally. It follows the completed Phase III FUEL trial (NCT02741115), which evaluated udenafil in a similar adolescent Fontan population. FUEL-2 is currently enrolling, and the Mezzion FUEL-2 trial financing is intended to sustain that enrollment momentum and broader operational execution.
Mezzion did not disclose the size of the financing round. The company, a US-based subsidiary of South Korean firm Mezzion Pharma Co., Ltd. (KOSDAQ: 140410), described the investors as institutional, but provided no further detail on terms or structure.
The announcement is notable in the context of rare disease pharmaceutical financing more broadly. Late-stage orphan programs with small, geographically dispersed patient populations are among the most capital-intensive in biopharma development, and securing institutional support for a confirmatory Phase III in a rare pediatric cardiac indication reflects continued investor appetite for programs with clearly defined unmet need, even in a constrained financing environment.
Fontan circulation: a disease without approved options
Fontan circulation arises from a series of staged surgical palliations performed in children born with single ventricle congenital heart disease — a group of structural cardiac defects in which only one of the two ventricles is functional. The Fontan procedure reroutes venous blood flow directly to the pulmonary arteries, bypassing the heart entirely. While this approach extends survival, it creates a chronically abnormal hemodynamic state characterized by elevated systemic venous pressure, reduced cardiac output, and impaired exercise capacity.
Patients with Fontan physiology face a progressive clinical trajectory. Exercise intolerance, arrhythmias, protein-losing enteropathy, and hepatic fibrosis are among the long-term sequelae. Median survival into adulthood has improved with surgical and medical advances, but the population remains at elevated risk of heart failure and early death compared with the general population. Despite the scale of morbidity, no pharmacologic therapy has been specifically approved for this indication by the US FDA or other major regulators.
That regulatory gap is central to Mezzion's development rationale. The company has framed udenafil as a potential first-in-class therapy specifically indicated for Fontan physiology — a designation that, if achieved, would represent the first approved pharmacologic option for this population.